Halozyme Therapeutics Inc (HALO)

Debt-to-equity ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	1,499,250	1,492,770	787,255	0	383,045
Total stockholders’ equity	US$ in thousands	83,808	169,798	196,953	151,047	91,765
Debt-to-equity ratio		17.89	8.79	4.00	0.00	4.17

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $1,499,250K ÷ $83,808K
= 17.89

The debt-to-equity ratio of Halozyme Therapeutics Inc. has been increasing over the past five years, indicating a higher reliance on debt financing compared to equity. The ratio was 17.89 at the end of 2023, a significant rise from 8.87 in 2022, 4.45 in 2021, 2.63 in 2020, and 4.39 in 2019. This suggests that the company has been taking on more debt relative to its equity levels, which may imply increased financial risk and potential challenges in servicing debt obligations. Further analysis of the company's overall financial health and debt management practices would be advisable to understand the implications of this trend.